U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H24N2O4.C4H6O6
Molecular Weight 494.4917
Optical Activity ( - )
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Arformoterol Tartrate

SMILES

O[C@H]([C@@H](O)C(O)=O)C(O)=O.COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC=C(O)C(NC=O)=C2)C=C1

InChI

InChIKey=FCSXYHUNDAXDRH-OKMNHOJOSA-N
InChI=1S/C19H24N2O4.C4H6O6/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22;5-1(3(7)8)2(6)4(9)10/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22);1-2,5-6H,(H,7,8)(H,9,10)/t13-,19+;1-,2-/m11/s1

HIDE SMILES / InChI

Molecular Formula C19H24N2O4
Molecular Weight 344.4049
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C4H6O6
Molecular Weight 150.0868
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/14725487

Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the beta(2)-adrenoceptor agonist formoterol [eformoterol]. This isomer contains two chiral canters and is being developed as an inhaled preparation for the treatment of respiratory disorders. Sepracor believes that arformoterol has the potential to be a once-daily therapy with a rapid onset of action and a duration of effect exceeding 12 hours. Sepracor stated in July 2003 that it had completed more than 100 preclinical studies and initiated or completed 15 clinical studies for arformoterol inhalation solution for the treatment of bronchospasm in patients with COPD. The pharmacologic effects of beta2-adrenoceptor agonist drugs, including arformoterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3′,5′-adenosine monophosphate (cyclic AMP). Increased intracellular cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. In vitro tests show that arformoterol is an inhibitor of the release of mast cell mediators, such as histamine and leukotrienes, from the human lung. Arformoterol also inhibits histamine-induced plasma albumin extravasation in anesthetized guinea pigs and inhibits allergen-induced eosinophil influx in dogs with airway hyper-responsiveness. The relevance of these in vitro and animal findings to humans is unknown.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
BROVANA

Approved Use

BROVANA Inhalation Solution is a long-acting beta2-adrenergic agonist (beta2-agonist) indicated for: Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. (1.1) Important limitations of use: BROVANA Inhalation Solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease. (1.2, 5.2) BROVANA Inhalation Solution is not indicated to treat asthma. (1.2) 1.1 Maintenance Treatment of COPD BROVANA (arformoterol tartrate) Inhalation Solution is indicated for the long-term, twice daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. BROVANA Inhalation Solution is for use by nebulization only. 1.2 Important Limitations of Use BROVANA Inhalation Solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease [see WARNINGS AND PRECAUTIONS (5.2)

Launch Date

2006
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4.3 pg/mL
15 μg 2 times / day steady-state, respiratory
dose: 15 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered:
ARFORMOTEROL plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
26.65 pg/mL
24 μg single, respiratory
dose: 24 μg
route of administration: Respiratory
experiment type: SINGLE
co-administered: BECLOMETHASONE 17-MONOPROPIONATE
FORMOTEROL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
22.3 nM
10 μg single, respiratory
dose: 10 μg
route of administration: Respiratory
experiment type: SINGLE
co-administered: MOMETASONE FUROATE
FORMOTEROL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
34.5 pg × h/mL
15 μg 2 times / day steady-state, respiratory
dose: 15 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered:
ARFORMOTEROL plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
104.52 pg × h/mL
24 μg single, respiratory
dose: 24 μg
route of administration: Respiratory
experiment type: SINGLE
co-administered: BECLOMETHASONE 17-MONOPROPIONATE
FORMOTEROL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
33.7 pM × h
10 μg single, respiratory
dose: 10 μg
route of administration: Respiratory
experiment type: SINGLE
co-administered: MOMETASONE FUROATE
FORMOTEROL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
26 h
15 μg 2 times / day steady-state, respiratory
dose: 15 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered:
ARFORMOTEROL plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
4.71 h
24 μg single, respiratory
dose: 24 μg
route of administration: Respiratory
experiment type: SINGLE
co-administered: BECLOMETHASONE 17-MONOPROPIONATE
FORMOTEROL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
48%
15 μg 2 times / day steady-state, respiratory
dose: 15 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered:
ARFORMOTEROL plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
37.5%
FORMOTEROL plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
20 ug 2 times / day steady, respiratory
Recommended
Dose: 20 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 20 ug, 2 times / day
Sources:
unhealthy, 40-90 years
n = 123
Health Status: unhealthy
Condition: COPD
Age Group: 40-90 years
Sex: M+F
Population Size: 123
Sources:
Other AEs: Diarrhea, Nausea...
Other AEs:
Diarrhea (6%)
Nausea (6%)
Nasopharyngitis (4%)
Dry mouth (4%)
Vomiting (3%)
Dizziness (3%)
Insomnia (3%)
Sources:
25 ug 2 times / day multiple, respiratory
Highest studied dose
Dose: 25 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 25 ug, 2 times / day
Sources: Page: p.21
unhealthy, 63.8
n = 147
Health Status: unhealthy
Condition: Chronic obstructive pulmonary disease
Age Group: 63.8
Sex: M+F
Population Size: 147
Sources: Page: p.21
30 ug 2 times / day multiple, respiratory (total)
Recommended
Dose: 30 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 30 ug, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Chronic obstructive pulmonary disease
Sources: Page: p.1
Disc. AE: Bronchospasm paradoxical...
AEs leading to
discontinuation/dose reduction:
Bronchospasm paradoxical (grade 4)
Sources: Page: p.1
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Other AEs: Angina pectoris, Angina unstable...
Other AEs:
Angina pectoris (serious, 3 patients)
Angina unstable (serious, 1 patient)
Atrial fibrillation (serious, 3 patients)
Cardio-respiratory arrest (serious, 2 patients)
Cor pulmonale (serious, 1 patient)
Coronary artery disease (serious, 3 patients)
Myocardial ischaemia (serious, 1 patient)
Vertigo (serious, 1 patient)
Iridocyclitis (serious, 1 patient)
Barrett's oesophagus (serious, 1 patient)
Diverticular perforation (serious, 1 patient)
Gastric ulcer haemorrhage (serious, 1 patient)
Gastritis erosive (serious, 1 patient)
Hiatus hernia (serious, 1 patient)
Intestinal perforation (serious, 1 patient)
Pancreatitis acute (serious, 1 patient)
Non-cardiac chest pain (serious, 3 patients)
Oedema peripheral (serious, 1 patient)
Cholecystitis (serious, 1 patient)
Bronchopneumonia (serious, 1 patient)
Clostridial infection (serious, 1 patient)
Clostridium difficile colitis (serious, 1 patient)
Gastroenteritis bacterial (serious, 1 patient)
Osteomyelitis (serious, 1 patient)
Osteotomy (serious, 1 patient)
Osteomyelitis acute (serious, 1 patient)
Postoperative wound infection (serious, 1 patient)
Sepsis (serious, 3 patients)
Urinary tract infection (serious, 1 patient)
Accidental overdose (serious, 1 patient)
Ankle fracture (serious, 1 patient)
Cervical vertebral fracture (serious, 1 patient)
Head injury (serious, 1 patient)
Incisional hernia (serious, 1 patient)
Open wound (serious, 1 patient)
Tibia fracture (serious, 1 patient)
Muscular weakness (serious, 1 patient)
Rotator cuff syndrome (serious, 1 patient)
Brain neoplasm (serious, 1 patient)
Metastases to lymph nodes (serious, 1 patient)
Oesophageal carcinoma (serious, 1 patient)
Squamous cell carcinoma (serious, 1 patient)
Throat cancer (serious, 1 patient)
Carotid artery disease (serious, 1 patient)
Headache (serious, 1 patient)
Ischaemic stroke (serious, 1 patient)
Sensory disturbance (serious, 1 patient)
Transient ischaemic attack (serious, 1 patient)
Major depression (serious, 2 patients)
Mental status changes (serious, 1 patient)
Nephropathy (serious, 1 patient)
Renal artery stenosis (serious, 1 patient)
Renal failure (serious, 1 patient)
Acute respiratory distress syndrome (serious, 1 patient)
Bronchiectasis (serious, 1 patient)
Hypoxia (serious, 1 patient)
Respiratory arrest (serious, 1 patient)
Urticaria (serious, 1 patient)
Aortic aneurysm (serious, 1 patient)
Hypertensive crisis (serious, 1 patient)
Hypotension (serious, 1 patient)
Iliac artery stenosis (serious, 2 patients)
Peripheral arterial occlusive disease (serious, 1 patient)
Bronchitis (below serious, 43 patients)
Nasopharyngitis (below serious, 38 patients)
Upper respiratory tract infection (below serious, 22 patients)
Headache (below serious, 35 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Dizziness 3%
20 ug 2 times / day steady, respiratory
Recommended
Dose: 20 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 20 ug, 2 times / day
Sources:
unhealthy, 40-90 years
n = 123
Health Status: unhealthy
Condition: COPD
Age Group: 40-90 years
Sex: M+F
Population Size: 123
Sources:
Insomnia 3%
20 ug 2 times / day steady, respiratory
Recommended
Dose: 20 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 20 ug, 2 times / day
Sources:
unhealthy, 40-90 years
n = 123
Health Status: unhealthy
Condition: COPD
Age Group: 40-90 years
Sex: M+F
Population Size: 123
Sources:
Vomiting 3%
20 ug 2 times / day steady, respiratory
Recommended
Dose: 20 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 20 ug, 2 times / day
Sources:
unhealthy, 40-90 years
n = 123
Health Status: unhealthy
Condition: COPD
Age Group: 40-90 years
Sex: M+F
Population Size: 123
Sources:
Dry mouth 4%
20 ug 2 times / day steady, respiratory
Recommended
Dose: 20 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 20 ug, 2 times / day
Sources:
unhealthy, 40-90 years
n = 123
Health Status: unhealthy
Condition: COPD
Age Group: 40-90 years
Sex: M+F
Population Size: 123
Sources:
Nasopharyngitis 4%
20 ug 2 times / day steady, respiratory
Recommended
Dose: 20 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 20 ug, 2 times / day
Sources:
unhealthy, 40-90 years
n = 123
Health Status: unhealthy
Condition: COPD
Age Group: 40-90 years
Sex: M+F
Population Size: 123
Sources:
Diarrhea 6%
20 ug 2 times / day steady, respiratory
Recommended
Dose: 20 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 20 ug, 2 times / day
Sources:
unhealthy, 40-90 years
n = 123
Health Status: unhealthy
Condition: COPD
Age Group: 40-90 years
Sex: M+F
Population Size: 123
Sources:
Nausea 6%
20 ug 2 times / day steady, respiratory
Recommended
Dose: 20 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 20 ug, 2 times / day
Sources:
unhealthy, 40-90 years
n = 123
Health Status: unhealthy
Condition: COPD
Age Group: 40-90 years
Sex: M+F
Population Size: 123
Sources:
Bronchospasm paradoxical grade 4
Disc. AE
30 ug 2 times / day multiple, respiratory (total)
Recommended
Dose: 30 ug, 2 times / day
Route: respiratory
Route: multiple
Dose: 30 ug, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Chronic obstructive pulmonary disease
Sources: Page: p.1
Upper respiratory tract infection below serious, 22 patients
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Headache below serious, 35 patients
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Nasopharyngitis below serious, 38 patients
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Bronchitis below serious, 43 patients
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Accidental overdose serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Acute respiratory distress syndrome serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Angina unstable serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Ankle fracture serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Aortic aneurysm serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Barrett's oesophagus serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Brain neoplasm serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Bronchiectasis serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Bronchopneumonia serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Carotid artery disease serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Cervical vertebral fracture serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Cholecystitis serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Clostridial infection serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Clostridium difficile colitis serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Cor pulmonale serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Diverticular perforation serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Gastric ulcer haemorrhage serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Gastritis erosive serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Gastroenteritis bacterial serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Head injury serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Headache serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Hiatus hernia serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Hypertensive crisis serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Hypotension serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Hypoxia serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Incisional hernia serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Intestinal perforation serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Iridocyclitis serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Ischaemic stroke serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Mental status changes serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Metastases to lymph nodes serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Muscular weakness serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Myocardial ischaemia serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Nephropathy serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Oedema peripheral serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Oesophageal carcinoma serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Open wound serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Osteomyelitis acute serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Osteomyelitis serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Osteotomy serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Pancreatitis acute serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Peripheral arterial occlusive disease serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Postoperative wound infection serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Renal artery stenosis serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Renal failure serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Respiratory arrest serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Rotator cuff syndrome serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Sensory disturbance serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Squamous cell carcinoma serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Throat cancer serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Tibia fracture serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Transient ischaemic attack serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Urinary tract infection serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Urticaria serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Vertigo serious, 1 patient
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Cardio-respiratory arrest serious, 2 patients
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Iliac artery stenosis serious, 2 patients
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Major depression serious, 2 patients
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Angina pectoris serious, 3 patients
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Atrial fibrillation serious, 3 patients
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Coronary artery disease serious, 3 patients
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Non-cardiac chest pain serious, 3 patients
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
Sepsis serious, 3 patients
15 ug 2 times / day steady, respiratory
Dose: 15 ug, 2 times / day
Route: respiratory
Route: steady
Dose: 15 ug, 2 times / day
Sources:
unhealthy
n = 420
Health Status: unhealthy
Condition: COPD
Population Size: 420
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
inconclusive
moderate [Ki 33 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no (co-administration study)
Comment: coadministration with paroxetine did not affect exposure to either drug
Page: 37, 52
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
inconclusive
major
minor
minor
minor
no
no
no
weak
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
no (co-administration study)
Comment: coadministration with paroxetine caused a slight increase in paroxetine; dose adjustment is not required when coadministered with therapeutic agents that are potent inhibitors of CYP2D6
Page: 17, 37
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Tachyphylaxis following regular use of formoterol in exercise-induced bronchospasm.
2001
The lung as a route for systemic delivery of therapeutic proteins and peptides.
2001
Safety of formoterol Turbuhaler at cumulative dose of 90 microg in patients with acute bronchial obstruction.
2001 Dec
Formoterol Turbuhaler for as-needed therapy in patients with mild acute exacerbations of COPD.
2001 Nov
Bronchodilating properties of the VIP receptor agonist Ro 25-1553 compared to those of formoterol on the guinea-pig isolated trachea.
2001 Nov 2
[Long-acting beta 2-stimulants].
2001 Oct
Glaucoma associated with metered-dose bronchodilator therapy.
2001 Oct
Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk).
2001 Oct
Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial.
2001 Oct 15
[How compliance is improved. Combined treatment of asthma].
2001 Oct 18
Adrenaline hypothesis: effect of formoterol on noradrenaline release.
2001 Oct-Dec
[The effect of triamcinolone, montelukast and formoterol on serum levels of il-4, IgE and clinical parameters in children with asthma].
2001 Sep
Clinical efficacy with formoterol in the absence of a response to salmeterol: a review.
2001 Sep
Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: a multicenter, randomized, open-label trial.
2001 Sep
In vitro aerosol performance and dose uniformity between the Foradile Aerolizer and the Oxis Turbuhaler.
2001 Winter
Formoterol Turbuhaler 4.5 microg (delivered dose) has a rapid onset and 12-h duration of bronchodilation.
2002
Biological actions of formoterol isomers.
2002
Onset of action following formoterol Turbuhaler and salbutamol pMDI in reversible chronic airway obstruction.
2002
A post-marketing surveillance study of formoterol (Foradil): its use in general practice in England.
2002
Pharmacogenetics, pharmacogenomics and airway disease.
2002
Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease.
2002 Apr
Cost-effectiveness of eformoterol Turbohaler versus salmeterol Accuhaler in children with symptomatic asthma.
2002 Apr
Dose-related effects of formoterol on airway responsiveness to adenosine 5'-monophosphate and histamine.
2002 Apr
New drugs 2002. Part II.
2002 Apr
Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD.
2002 Apr
[The effect of triamcinolone acetonide, montelukast, nedocromil sodium, formoterol on levels levels of sICAM-1, sIL-2R in serum and clinical course of asthma in children].
2002 Feb
A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and beta-agonist treatment on IL-10 serum levels in children with asthma.
2002 Feb
Potential masking effect on dyspnoea perception by short- and long-acting beta2-agonists in asthma.
2002 Feb
The role of inflammation and anti-inflammatory medication in asthma.
2002 Feb
The whole story: treatment outcomes with Symbicort.
2002 Feb
Symbicort: controlling asthma in children.
2002 Feb
Symbicort: controlling asthma in adults.
2002 Feb
Acute formoterol administration has no ergogenic effect in nonasthmatic athletes.
2002 Feb
Formoterol fumarate.
2002 Feb 15
The safety and efficacy of formoterol (Oxis) turbuhaler plus budesonide (Pulmicort) turbuhaler in mild to moderate asthma: a comparison with budesonide Turbuhaler alone and current non-corticosteroid therapy in Russia.
2002 Jan-Feb
Low-dose budesonide improved asthma control in mild asthma; adding formoterol improved control in corticosteroid-treated patients.
2002 Jul-Aug
Relative therapeutic index between inhaled formoterol and salbutamol in asthma patients.
2002 Jun
Delivery of formoterol from a novel multi-dose inhaler Airmax.
2002 Jun
Beta-adrenoceptor agonists and asthma--100 years of development.
2002 Jun 7
[Effect of triamcinolone acetonide, montelukast, nedocromil sodium and formoterol on eosinophil blood counts, ECP serum levels and clinical progression of asthma in children].
2002 Mar
Is the increase in bronchial responsiveness or FEV1 shortly after cessation of beta2-agonists reflecting a real deterioration of the disease in allergic asthmatic patients? A comparison between short-acting and long-acting beta2-agonists.
2002 Mar
Additive anti-inflammatory effect of formoterol and budesonide on human lung fibroblasts.
2002 Mar
New therapeutic drugs in the management of chronic obstructive pulmonary disease.
2002 Mar
Quantification of terbutaline in urine by enzyme-linked immunosorbent assay and capillary electrophoresis after oral and inhaled administrations.
2002 Mar 5
Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study.
2002 Mar-Apr
Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma.
2002 May
Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial.
2002 May
Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline.
2002 May
Comparison of the effects of salmeterol and formoterol in patients with severe asthma.
2002 May
[Asthma therapy. Long-term spasmolytic therapy with rapid effect].
2002 May 23
Patents

Sample Use Guides

15 ug administered twice a day (morning and evening) by nebulization. A total daily dose greater than 30 ug (15 ug twice daily) is not recommended. BROVANA (arformoterol tartrate) should be administered by the inhaled route via a standard jet nebulizer connected to an air compressor
Route of Administration: Respiratory
In Vitro Use Guide
Curator's Comment: In vitro tests show that arformoterol is an inhibitor of the release of mast cell mediators, such as histamine and leukotrienes, from the human lung. Arformoterol also inhibits histamine-induced plasma albumin extravasation in anesthetized guinea pigs and inhibits allergen-induced eosinophil influx in dogs with airway hyper-responsiveness.
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:03:13 GMT 2023
Edited
by admin
on Fri Dec 15 16:03:13 GMT 2023
Record UNII
5P8VJ2I235
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Arformoterol Tartrate
MART.   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN  
Official Name English
ARFORMOTEROL TARTRATE [MART.]
Common Name English
Arformoterol tartrate [WHO-DD]
Common Name English
FORMAMIDE, N-(2-HYDROXY-5-((1R)-1-HYDROXY-2-(((1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL)AMINO)ETHYL)PHENYL)-, (2R,3R)-2,3-DIHYDROXYBUTANEDIOATE (1:1) (SALT)
Common Name English
FORMOTEROL R,R-FORM L-TARTRATE [MI]
Common Name English
ARFORMOTEROL TARTRATE [USAN]
Common Name English
ARFORMOTEROL TARTRATE [ORANGE BOOK]
Common Name English
BROVANA
Brand Name English
ARFORMOTEROL TARTRATE [VANDF]
Common Name English
(-)-N-(2-HYDROXY-5-((1R)-1-HYDROXY-2-(((1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL)AMINO)ETHYL)PHENYL)FORMAMIDE HYDROGEN (2R,3R)-2,3-DIHYDROXYBUTANEDIOATE (SALT)
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C319
Created by admin on Fri Dec 15 16:03:13 GMT 2023 , Edited by admin on Fri Dec 15 16:03:13 GMT 2023
NCI_THESAURUS C48149
Created by admin on Fri Dec 15 16:03:13 GMT 2023 , Edited by admin on Fri Dec 15 16:03:13 GMT 2023
Code System Code Type Description
USAN
OO-79
Created by admin on Fri Dec 15 16:03:13 GMT 2023 , Edited by admin on Fri Dec 15 16:03:13 GMT 2023
PRIMARY
CAS
200815-49-2
Created by admin on Fri Dec 15 16:03:13 GMT 2023 , Edited by admin on Fri Dec 15 16:03:13 GMT 2023
PRIMARY
DRUG BANK
DBSALT001387
Created by admin on Fri Dec 15 16:03:13 GMT 2023 , Edited by admin on Fri Dec 15 16:03:13 GMT 2023
PRIMARY
MERCK INDEX
m5542
Created by admin on Fri Dec 15 16:03:13 GMT 2023 , Edited by admin on Fri Dec 15 16:03:13 GMT 2023
PRIMARY Merck Index
EVMPD
SUB32085
Created by admin on Fri Dec 15 16:03:13 GMT 2023 , Edited by admin on Fri Dec 15 16:03:13 GMT 2023
PRIMARY
PUBCHEM
9827062
Created by admin on Fri Dec 15 16:03:13 GMT 2023 , Edited by admin on Fri Dec 15 16:03:13 GMT 2023
PRIMARY
SMS_ID
100000124467
Created by admin on Fri Dec 15 16:03:13 GMT 2023 , Edited by admin on Fri Dec 15 16:03:13 GMT 2023
PRIMARY
NCI_THESAURUS
C65240
Created by admin on Fri Dec 15 16:03:13 GMT 2023 , Edited by admin on Fri Dec 15 16:03:13 GMT 2023
PRIMARY
FDA UNII
5P8VJ2I235
Created by admin on Fri Dec 15 16:03:13 GMT 2023 , Edited by admin on Fri Dec 15 16:03:13 GMT 2023
PRIMARY
RXCUI
668284
Created by admin on Fri Dec 15 16:03:13 GMT 2023 , Edited by admin on Fri Dec 15 16:03:13 GMT 2023
PRIMARY RxNorm
ChEMBL
CHEMBL1363
Created by admin on Fri Dec 15 16:03:13 GMT 2023 , Edited by admin on Fri Dec 15 16:03:13 GMT 2023
PRIMARY
EPA CompTox
DTXSID80173903
Created by admin on Fri Dec 15 16:03:13 GMT 2023 , Edited by admin on Fri Dec 15 16:03:13 GMT 2023
PRIMARY
DAILYMED
5P8VJ2I235
Created by admin on Fri Dec 15 16:03:13 GMT 2023 , Edited by admin on Fri Dec 15 16:03:13 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY